Lewis A (Le^a) is a fucosylated trisaccharide antigen within the histo-blood group carbohydrate family, characterized by the structure Galβ(1→3)[Fucα(1→4)]GlcNAcβ, where galactose (Gal) links β1-3 to N-acetylglucosamine (GlcNAc), and fucose (Fuc) attaches α1-4 to the same GlcNAc residue. This type I chain differs from type II chains like Lewis X by the β1-3 Gal-GlcNAc linkage instead of β1-4. The core monosaccharides—Gal, Fuc, and GlcNAc—contribute to its specificity, with NMR signals aiding structural confirmation, such as H-1 at ~4.70 ppm for GlcNAc and ~4.65 ppm for the terminal Gal.

Biosynthesis and Genetic Basis

Synthesis of Lewis A relies on fucosyltransferases encoded by the FUT3 gene, adding α1-4 Fuc to the type I precursor Galβ1-3GlcNAc, while the secretor FUT2 gene adds α1-2 Fuc to form difucosylated Lewis B. Le^a expression predominates in non-secretors (se/se genotype) with active FUT3, appearing in secretions like milk and plasma, and correlating with Lewis blood group phenotyping. Elongation often occurs in Le^a-carrying chains, unlike shorter Le^b structures.

Biological Roles and Clinical Relevance

Lewis A antigens function in cell adhesion, serving as ligands for selectins during inflammation and contributing to sialyl Lewis A (sLe^a) in cancer metastasis. Found on glycoproteins and glycolipids in human milk oligosaccharides, they influence microbial interactions and immune responses. In oncology, Le^y (a related antigen) marks tumor cells, prompting synthesis efforts for therapeutic targets.

Synthetic Approaches

Automated glycan assembly and orthogonal glycosylation enable efficient Le^a production, using fucosyl fluorides and selective deprotection to build the trisaccharide core. These methods yield pure antigens for studies, often extending to longer chains like KH-1 nonasaccharide. Structural elucidation employs MS fragmentation (B/Y ions) and NMR for linkage verification.